Rhythm Pharmaceuticals, Inc. (RYTM)
Automate Your Wheel Strategy on RYTM
With Tiblio's Option Bot, you can configure your own wheel strategy including RYTM - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol RYTM
- Rev/Share 2.1704
- Book/Share 2.5863
- PB 23.9262
- Debt/Equity 0.0249
- CurrentRatio 3.3024
- ROIC -0.628
- MktCap 3936898420.0
- FreeCF/Share -1.1654
- PFCF -53.5727
- PE -22.9507
- Debt/Assets 0.0105
- DivYield 0
- ROE -1.7982
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | RYTM | BofA Securities | Neutral | Buy | -- | $63 | April 7, 2025 |
| Resumed | RYTM | Stifel | -- | Buy | -- | $78 | March 5, 2025 |
| Initiation | RYTM | Jefferies | -- | Buy | -- | $80 | Jan. 2, 2025 |
| Initiation | RYTM | Oppenheimer | -- | Outperform | -- | $76 | Dec. 20, 2024 |
| Initiation | RYTM | Guggenheim | -- | Buy | -- | $70 | Oct. 21, 2024 |
| Initiation | RYTM | H.C. Wainwright | -- | Buy | -- | $64 | Sept. 18, 2024 |
| Initiation | RYTM | JMP Securities | -- | Mkt Outperform | -- | $64 | Sept. 17, 2024 |
News
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q1 Loss, Lags Revenue Estimates
Published: May 07, 2025 by: Zacks Investment Research
Sentiment: Negative
Rhythm Pharmaceuticals, Inc. (RYTM) came out with a quarterly loss of $0.81 per share versus the Zacks Consensus Estimate of a loss of $0.69. This compares to loss of $2.35 per share a year ago.
Read More
Rhythm Pharmaceuticals Reports First Quarter 2025 Financial Results and Business Update
Published: May 07, 2025 by: GlobeNewsWire
Sentiment: Neutral
-- First quarter 2025 net product revenue from global sales of IMCIVREE ® (setmelanotide) of $37.7 million -- -- Setmelanotide pivotal Phase 3 TRANSCEND trial met primary endpoint with -19.8% placebo-adjusted BMI reduction in patients (N=120) with acquired hypothalamic obesity --
Read More
Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences
Published: May 06, 2025 by: GlobeNewsWire
Sentiment: Neutral
BOSTON, May 06, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that David Meeker, M.D., Chair, President and Chief Executive Officer, will participate in fireside chats at three upcoming investor conferences: Bank of America Securities 2025 Healthcare Conference on Wednesday, May 14, 2025 at 12:20 a.m.
Read More
Rhythm Pharmaceuticals (RYTM) Moves 5.2% Higher: Will This Strength Last?
Published: April 25, 2025 by: Zacks Investment Research
Sentiment: Positive
Rhythm Pharmaceuticals (RYTM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Read More
Rhythm: Late-Stage Study Win Brings About Change For Rare Obesity Disorder
Published: April 08, 2025 by: Seeking Alpha
Sentiment: Positive
Rhythm Pharmaceuticals, Inc. met primary endpoint in phase 3 TRANSCEND study, which used setmelanotide for the treatment of patients with acquired hypothalamic obesity. Regulatory submission of setmelanotide to the U.S. and EU, for the treatment of patients with acquired hypothalamic obesity, expected in Q3 of 2025. Company pushing forward with oral MC4R-specific agonist to treat patients with acquired hypothalamic obesity known as bivamelagon;
Read More
RYTM Stock Rises 17% on Meeting Goals in Hypothalamic Obesity Study
Published: April 08, 2025 by: Zacks Investment Research
Sentiment: Positive
Rhythm Pharmaceuticals stock gains 17% on meeting goals with statistical significance in the late-stage acquired hypothalamic obesity study for setmelanotide.
Read More
Rhythm Pharmaceuticals, Inc. (RYTM) Q4 2024 Earnings Call Transcript
Published: February 26, 2025 by: Seeking Alpha
Sentiment: Neutral
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM ) Q4 2024 Earnings Conference Call February 26, 2025 8:00 AM ET Company Participants David Connolly – Investor Relations and Corporate Communications David Meeker – Chairman, Chief Executive Officer and President Jennifer Lee – Executive Vice President, Head-North America Hunter Smith – Chief Financial Officer Yann Mazabraud – Executive Vice President, Head-International Conference Call Participants Derek Archila – Wells Fargo Seamus Fernandez – Guggenheim Securities Phil Nadeau – TD Cowen Whitney Ijem – Canaccord Genuity Tazeen Ahmad – Bank of America Joseph Stringer – Needham & Company Leland Gershell – Oppenheimer Anthea Li – Jefferies Ram …
Read More
Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Business Update
Published: February 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
-- Fourth quarter 2024 net revenue from global sales of IMCIVREE® (setmelanotide) of $41.8 million -- -- On track to report topline data from global Phase 3 trial evaluating setmelanotide in acquired hypothalamic obesity in the second quarter of 2025 -- -- Completed enrollment in the Phase 2 trial of oral MC4R agonist bivamelagon in acquired hypothalamic obesity -- -- FDA approved expanded label for IMCIVREE to include children as young as 2 years old -- -- Raised approximately $75 million in gross proceeds under ATM equity offering program; Cash runway extended into 2027 -- -- Management to host conference …
Read More
Rhythm Pharmaceuticals: Buying This Rare Genetic Obesity Maven
Published: February 25, 2025 by: Seeking Alpha
Sentiment: Positive
Rhythm Pharmaceuticals' 01/2025 presentation and Q4 2024 preliminary results press release highlight growing financial performance and promising pipeline developments. Investment thesis focuses on Rhythm's robust clinical progress and strategic positioning in the rare genetic obesity market. Rating justification is based on solid revenues, innovative product pipeline, and potential market expansion.
Read More
Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on Wednesday, February 26, 2025
Published: February 13, 2025 by: GlobeNewsWire
Sentiment: Neutral
BOSTON, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Wednesday, February 26, 2025 to report its fourth quarter and full year 2024 financial results and provide a corporate update.
Read More
About Rhythm Pharmaceuticals, Inc. (RYTM)
- IPO Date 2017-10-09
- Website https://www.rhythmtx.com
- Industry Biotechnology
- CEO Dr. David P. Meeker M.D.
- Employees 283